Selected for NEDO’s Deep Tech Startup Support Project PCA Phase (Practical Application R&D (Late Stage)).

MiCAN Technologies Inc. has been selected by the New Energy and Industrial Technology Development Organization (NEDO) for the “PCA Phase (Practical Application R&D (late stage))” of the “Deep Tech Startup Support Project.

The “Deep Tech Startup Support Project” is an initiative to support the research and development of innovative technologies that require long-term R&D and large-scale funding to establish the technology, commercialize it, and implement it in society, and that are considered to contribute to solving economic and social issues that should be addressed by the nation and the world as a whole, despite their high risk. The PCA phase is a support program for the development of prototypes and initial production technology development, as well as the implementation of a feasibility study for commercialization in order to capture major markets.

The grant projects selected for the PCA phase are as follows

・Title of the grant project: Development of MylcMAT products using immortalized monocyte cells aMylc

・Project period: September 22, 2023 – March 31, 2025

・Partner VC: Realtech Japan, LLC

This adoption will be an opportunity to accelerate the market development of MAT test kits using human-derived immortalized myeloid cells (Mylc cells) products that we are currently offering. Currently, when manufacturing and selling pharmaceuticals and medical devices, it is required by law to conduct safety tests to ensure that they are not contaminated by microorganisms such as viruses and bacteria, and the rabbit pyrogen test and the LAL test using horseshoe crabs are mainly approved and applied. From the perspective of animal protection and the realization of a sustainable society (SDG’s), there is a need to develop a test method that does not use materials such as rabbits and horseshoe crabs, and the Monocyte Activation Test that we are currently developing is an alternative to the conventional test method. We will contribute to people’s health through the development and commercialization of safety test kits using special cells that utilize our regenerative medicine technology.

For more information(PDF)→